SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin rises on receiving final USFDA approval for Moxifloxacin Hydrochloride Tablets

17 Feb 2017 Evaluate

Lupin is currently trading at Rs. 1452.00, up by 11.85 points or 0.82% from its previous closing of Rs. 1440.15 on the BSE.

The scrip opened at Rs. 1449.00 and has touched a high and low of Rs. 1457.00 and Rs. 1445.75 respectively. So far 13,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1874.30 on 14-Mar-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.

Last one week high and low of the scrip stood at Rs. 1478.95 and Rs. 1425.00 respectively. The current market cap of the company is Rs. 65,496.00 crore.

The promoters holding in the company stood at 46.71%, while Institutions and Non-Institutions held 41.46% and 11.83% respectively.

Lupin has received final US Food and Drug Administration (USFDA) approval for ANDA Moxifloxacin Hydrochloride Tablets, 400 mg, generic of Avlox Tablets of Bayer Healthcare Pharmaceuticals, Inc.

The company has recently received final approval for its Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% from the USFDA to market a generic equivalent of Mylan Pharmaceuticals Inc.’s Triamcinolone Acetonide Cream, 0.025% and 0.1%.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.


Lupin Share Price

2459.75 17.40 (0.71%)
07-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1834.40
Dr. Reddys Lab 1306.80
Cipla 1362.85
Zydus Lifesciences 940.10
Lupin 2459.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×